HCEG Healthcare Ent.

RNS Number:5123Y
Healthcare Enterprise Group PLC
11 May 2004

Healthcare Enterprise Group PLC

Ebiox milestones achieved - deferred consideration for the purchase of SafaTec
stake

Healthcare Enterprise Group ("HCEG" or the "Group") is pleased to announce that
as a result of certain pre-agreed milestones being reached by Ebiox Limited,
which is 49% owned by HCEG, deferred consideration has become payable to the
vendors of the 60.7% stake in SafaTec (UK) Limited ("SafaTec") acquired by HCEG
in November 2003.

The acquisition of the 60.7% stake in SafaTec gave the Group access to a
pipeline of innovative healthcare products.  One such product is Ebiox, which is
a range of proprietary cleansing and decontamination products for use in the
healthcare industry.  The surface and instrument decontamination products are
now being rolled out in the UK and USA, and are already being used in over 50
National Health Service hospitals.

In February 2004 the US Environmental Protection Agency ("EPA") gave its
approval for a range of five of Ebiox's decontamination products to be
distributed in the US.  HCEG, through its operations in the US, will be pivotal
to the marketing process of these products.

An additional milestone achieved in March 2004 relates to Ebiox wipes being
included in the 2004 NHS Catalogue of approved products.  A distribution
agreement was subsequently entered into between the NHS Purchasing and Supply
Agency and Ebiox's UK distributor, Vernon-Carus Limited, resulting in Ebiox
multi-surface decontamination wipes being approved for use by all NHS hospitals.

HCEG considers these two milestones to be of fundamental importance to the
group's strategy of distributing Ebiox products to the widest possible customer
base.



Deferred Consideration

The EPA approval and the inclusion of Ebiox products in the 2004 NHS Catalogue
each constitute milestones triggering the payment of deferred consideration
under the agreement entered into by HCEG on 18 October 2003 for the purchase by
HCEG of a 60.7% equity stake in SafaTec (UK) Limited (the "SafaTec Agreement").
Details of the SafaTec Agreement, including the terms of the deferred
consideration payable by HCEG, were summarised in paragraph 4 of Part I and in
paragraph 12.1.12 of Part X of the prospectus issued by HCEG on 20 October 2003
(the "Prospectus").   The SafaTec Agreement provides that ordinary shares of
0.1p each in the capital of HCEG ("Ordinary Shares") to the value of #832,000
are to be issued upon the attainment of each of these milestones at issue prices
calculated in accordance with the terms of the SafaTec Agreement summarised in
the Prospectus.  As a consequence of the attainment of the first two milestones,
103,759,069 Ordinary Shares in aggregate are to be issued by way of deferred
consideration to the vendors under the SafaTec Agreement as follows:

1.   69,343,934 Ordinary Shares to Gordon Wood, Chief Executive Officer,
     Products and Distribution Division;

2.   18,149,276 Ordinary Shares to Goosec Limited;

3.   11,985,371 Ordinary Shares to the trustees of the Safa Trust, a trust
     connected with Gordon Wood; and

4.   4,280,488 Ordinary Shares to Sinitus Nominees Limited.

Application is being made for these Ordinary Shares to be admitted to trading on
AIM.

                                                                     11 May 2004

Enquiries:

Healthcare Enterprise Group PLC                        Tel: 020 7659 6158
Stuart Bruck, Executive Chairman

College Hill                                           Tel: 020 7457 2020
Nicholas Nelson/ Corinna Dorward



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCBIGDUDGBGGSG

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jul 2023 to Jul 2024